Gyre Therapeutics (NASDAQ:GYRE) Stock Gets Downgrade from Wall Street Zen

Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other analysts have also recently issued reports on GYRE. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce”.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $6.08 on Friday. The firm’s fifty day moving average price is $6.88 and its 200 day moving average price is $6.73. Gyre Therapeutics has a 12 month low of $5.44 and a 12 month high of $9.14. The company has a market capitalization of $677.98 million, a price-to-earnings ratio of -28.95 and a beta of 1.89.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $26.49 million. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. As a group, sell-side analysts forecast that Gyre Therapeutics will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE purchased a new position in shares of Gyre Therapeutics during the second quarter worth about $83,000. BlackRock Inc. purchased a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $6,550,000. Deutsche Bank AG purchased a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $118,000. Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $414,000. Finally, Dimensional Fund Advisors LP lifted its position in Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after acquiring an additional 14,365 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, with an emphasis on liver fibrosis and other serious chronic conditions. The company’s research and development activities are centered on novel small-molecule treatments intended to address the underlying processes that cause excessive scar tissue formation.

Gyre’s lead investigational product is F351, also known as hydronidone, a potential treatment for liver fibrosis. The therapy has been studied in China for hepatitis B virus-associated liver fibrosis and is also being evaluated in the United States for liver fibrosis associated with nonalcoholic steatohepatitis.